KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash & Current Investments (2016 - 2025)

Sarepta Therapeutics has reported Cash & Current Investments over the past 16 years, most recently at $939.6 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 14.26% year-over-year to $939.6 million; the TTM value through Dec 2025 reached $939.6 million, down 14.26%, while the annual FY2025 figure was $939.6 million, 14.26% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $939.6 million at Sarepta Therapeutics, up from $851.0 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $2.1 billion in Q4 2021 and troughed at $242.5 million in Q3 2024.
  • A 5-year average of $1.5 billion and a median of $1.7 billion in 2021 define the central range for Cash & Current Investments.
  • Biggest five-year swings in Cash & Current Investments: plummeted 86.01% in 2024 and later surged 250.97% in 2025.
  • Year by year, Cash & Current Investments stood at $2.1 billion in 2021, then fell by 5.98% to $2.0 billion in 2022, then fell by 15.74% to $1.7 billion in 2023, then crashed by 34.62% to $1.1 billion in 2024, then dropped by 14.26% to $939.6 million in 2025.
  • Business Quant data shows Cash & Current Investments for SRPT at $939.6 million in Q4 2025, $851.0 million in Q3 2025, and $800.1 million in Q2 2025.